These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26885437)

  • 1. Intravenous Immunoglobulins: Mode of Action and Indications in Autoimmune and Inflammatory Dermatoses.
    Dourmishev LA; Guleva DV; Miteva LG
    Int J Inflam; 2016; 2016():3523057. PubMed ID: 26885437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulins for treatment of connective tissue diseases in dermatology.
    Dourmishev LA; Guleva DV; Miteva LG
    Wien Med Wochenschr; 2018 Jun; 168(9-10):213-217. PubMed ID: 28864939
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose intravenous immunoglobulins for the treatment of dermatological autoimmune diseases.
    Hoffmann JHO; Enk AH
    J Dtsch Dermatol Ges; 2017 Dec; 15(12):1211-1226. PubMed ID: 29228499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine.
    Velikova T; Sekulovski M; Bogdanova S; Vasilev G; Peshevska-Sekulovska M; Miteva D; Georgiev T
    Antibodies (Basel); 2023 Mar; 12(1):. PubMed ID: 36975367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intravenous immunoglobulins: perspectives in multiple sclerosis (a literature review with own results)].
    Bisaga GN; Skulyabin ID; Popov AE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(8. Vyp. 2):36-43. PubMed ID: 28635713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunochemical-based assays in the bioanalysis of immunoglobulins.
    Lamari F; Anastassiou ED; Dimitracopoulos G; Karamanos NK
    J Pharm Biomed Anal; 2000 Nov; 23(6):939-46. PubMed ID: 11095294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Treatment with Zinc Aspartate and Intravenous Immunoglobulins (IVIGs) Ameliorates Experimental Autoimmune Encephalomyelitis (EAE).
    Straubel D; Thielitz A; Reinhold A; Grüngreiff K; Reinhold D
    J Immunol Res; 2018; 2018():5982169. PubMed ID: 30356433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update.
    Czernik A; Toosi S; Bystryn JC; Grando SA
    Autoimmunity; 2012 Feb; 45(1):111-8. PubMed ID: 21923613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous immunoglobulin in autoimmune and inflammatory dermatoses. A review of proposed mechanisms of action and therapeutic applications.
    Colsky AS
    Dermatol Clin; 2000 Jul; 18(3):447-57, ix. PubMed ID: 10943540
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human immunoglobulins in intraocular inflammation.
    Tellier Z
    Ann N Y Acad Sci; 2007 Sep; 1110():337-47. PubMed ID: 17911449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria for the appropriate drug utilisation of immunoglobulin.
    Thürmann P; Harder S
    Pharmacoeconomics; 1996 May; 9(5):417-29. PubMed ID: 10160254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca(2+)-dependent signal transduction through Fc gamma receptors in B lymphocytes.
    Kondo N; Kasahara K; Kameyama T; Suzuki Y; Shimozawa N; Tomatsu S; Nakashima Y; Hori T; Yamagishi A; Ogawa T
    Scand J Immunol; 1994 Jul; 40(1):37-42. PubMed ID: 8029641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin: properties, mode of action and practical use in dermatology.
    Prins C; Gelfand EW; French LE
    Acta Derm Venereol; 2007; 87(3):206-18. PubMed ID: 17533485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.
    Martinez V; Cohen P; Pagnoux C; Vinzio S; Mahr A; Mouthon L; Sailler L; Delaunay C; Sadoun A; Guillevin L;
    Arthritis Rheum; 2008 Jan; 58(1):308-17. PubMed ID: 18163506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Intravenous immunoglobulins: therapeutic indications].
    Mouthon L; Berezné A; Le Guern V; Guillevin L
    Presse Med; 2005 Sep; 34(16 Pt 1):1166-75. PubMed ID: 16208266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk.
    Dantal J
    Am J Nephrol; 2013; 38(4):275-84. PubMed ID: 24051350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IgG, IgA and C3 deposits in the extra-thyroidal manifestations of autoimmune Graves' disease: their in vitro solubilization by intravenous immunoglobulin.
    Antonelli A; Palla R; Casarosa L; Fallahi P; Baschieri L
    Clin Exp Rheumatol; 1996; 14 Suppl 15():S31-5. PubMed ID: 8828945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A place of intravenous immunoglobulins in current clinical practice: Privigen is a novel 10% immunoglobulin].
    Latysheva TV; Latysheva EA; Martynova IA
    Ter Arkh; 2016; 88(4):82-87. PubMed ID: 27070168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulatory effects of intravenous immunoglobulins (IVIGs) in HIV-1 disease: a systematic review.
    Pastori D; Esposito A; Mezzaroma I
    Int Rev Immunol; 2011 Feb; 30(1):44-66. PubMed ID: 21171862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravenous immunoglobulins in dermatology. Part 2: clinical indications and outcomes.
    Forbat E; Ali FR; Al-Niaimi F
    Clin Exp Dermatol; 2018 Aug; 43(6):659-666. PubMed ID: 29774587
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.